0000000000962013

AUTHOR

M.t. Fierro

showing 2 related works from this author

Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients.

2019

Background: Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease characterized by a significant impairment of patients’ quality of life (QoL). It has been recently found that clinical severity of HS does not correlate well with QoL. Therefore, it is important to enhance the evaluation of severity considering the disease burden on QoL. Recently, a new graphical tool able to better describe HS burden, the so-called HIDRAdisk, has been introduced. Objective: To investigate the utility of HIDRAdisk in clinical practice before and after treatment and to analyse whether specific factors such as age and gender may influence the outcomes in patients with moderate-to-severe…

AdultMalemedicine.medical_specialtyVisual Analog ScaleDermatology.Severity of Illness IndexAge and gender030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsDisease severityQuality of lifeHidradenitis suppurativa quality of lifeCost of IllnessInternal medicinemedicineAdalimumabHumansIn patientHidradenitis suppurativa030212 general & internal medicineDisease burdenRetrospective Studiesbusiness.industryAge FactorsRetrospective cohort studyMiddle Agedmedicine.diseaseHidradenitis SuppurativaInfectious DiseasesTreatment OutcomeQuality of LifeFemalebusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEHIDRAdisk outcomesmedicine.drughidradiskJournal of the European Academy of Dermatology and Venereology : JEADVReferences
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct